SCHEMBL2962035

SCHEMBL2962035

COc1ccc(Sc2ccc(C)cc2Nc2ccnc3nc(C)ccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.43
AKT2 P31751 1/20 0.43
HTR1A P08908 3/20 0.38
HTR3A P46098 2/20 0.38
PTGIR P43119 1/20 0.37
KDR P35968 2/20 0.36
PDGFRA P16234 1/20 0.36
RIPK2 O43353 2/20 0.35
SYK P43405 1/20 0.35
AURKB Q96GD4 1/20 0.35
INCENP Q9NQS7 1/20 0.35
DYRK1A Q13627 1/20 0.34
HTT P42858 1/20 0.34
GAK O14976 1/20 0.34
COQ8A Q8NI60 1/20 0.34
NLK Q9UBE8 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
TERT O14746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2968986 0.91 PIM1 (0.41) PIM1AKT2HTR1AHTR3AKDR
SCHEMBL2961106 0.90 PIM1 (0.44) PIM1AKT2HTR1APTGIRSYK
SCHEMBL2964092 0.89 PIM1 (0.42) PIM1AKT2PTGIRALDH1A1MAPT
SCHEMBL2968994 0.89 PIM1 (0.37) PIM1AKT2HTR1AHTR3APTGIR
SCHEMBL2961811 0.89 PIM1 (0.46) PIM1AKT2PTGIRKDRHTT
SCHEMBL2970313 0.88 PIM1 (0.45) PIM1AKT2HTR1AALDH1A1MAPT
SCHEMBL2955657 0.88 KMT2A (0.38) PIM1AKT2KDRAURKBHTT
SCHEMBL2960399 0.88 PIM1 (0.47) PIM1AKT2HTR1APTGIRKDR
SCHEMBL2022784 0.87 PIM1 (0.39) PIM1AKT2HTR1AKDRHTT
SCHEMBL2968944 0.87 PIM1 (0.39) PIM1AKT2HTR1AHTR3AGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885HTR1A 4760/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885HTR1A 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.